Seres Therapeutics Inc. (MCRB)
NASDAQ: MCRBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MCRB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $12.64M
- EPS (TTM)
- -$5.01
- Dividend yield
- None
- 52-week range
- 1.20 – 18.86
- Day range
- 1.20 – 1.36
- Volume / Avg
- 56.76K / 74.83K
- Beta
- —
- Shares outstanding
- 10.20M
52-week range
MCRB stock today
Seres Therapeutics (MCRB) closed at $1.24 on Nov 20, down 6.77% (-$0.09), versus the S&P 500's 3.70% decline. At this level, MCRB sits near the bottom of its 52-week range of $1.20 to $18.86: 93.4% below the high and 3.2% above the low. Seres Therapeutics has posted a net loss over the last twelve months (EPS of -$5.01), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Seres Therapeutics
Company profileSeres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Richard N. Kender B.S., M.B.A.
- Headquarters
- Cambridge, MA
- Employees
- 66
- IPO year
- 2015
- Website
- serestherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Seres Therapeutics generated $789,000 in revenue, up 0.0% from fiscal 2024. Net income was $5.7 million (+4088.2% year over year), for a net margin of 721.9% versus a median of -268.3% in the prior 5 years. Operating margin was -11910.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $789.00K | $0 | $0 | $7.13M | $144.93M |
| Growth | — | — | -100.00% | -95.08% | +336.33% |
| Net income | $5.70M | $136.00K | $-113.72M | $-250.16M | $-65.58M |
| EPS (diluted) | $0.64 | $0.00 | $-17.77 | $-2.31 | $-0.72 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$17.00+1270.97%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-1.63 vs $-1.34
- Surprise
- -21.64%
MCRB news
All MCRB news- Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)GlobeNewswire
- Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026GlobeNewswire
Seres Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NEUPNeuphoria Therapeutics Inc. | 2.35 | +1.29% | $12.72M | vs MCRB |
| ALLRAllarity Therapeutics Inc. | 0.785 | -9.25% | $12.56M | vs MCRB |
| BOLTBolt Biotherapeutics Inc. | 4.91 | -2.96% | $12.80M | vs MCRB |
| MIRAMIRA Pharmaceuticals Inc. | 0.291 | -20.84% | $12.23M | vs MCRB |
| TVRDTvardi Therapeutics Inc. | 0.9893 | +4.57% | $13.22M | vs MCRB |
| ACTUActuate Therapeutics Inc. | 0.2253 | +5.38% | $13.60M | vs MCRB |
| BYSIBeyondSpring Inc. | 0.33 | -24.49% | $13.66M | vs MCRB |
| CTXRCitius Pharmaceuticals Inc. | 0.5085 | +2.27% | $13.96M | vs MCRB |
Indexes, lists and sector
Seres Therapeutics stock FAQ
What is Seres Therapeutics's stock price today?
MCRB last traded at $1.24 as of Nov 20, 4:00 PM EST, down 6.77% on the day. Prices are delayed at least 15 minutes.
Who is Seres Therapeutics's CEO?
Mr. Richard N. Kender B.S., M.B.A. is the chief executive officer of Seres Therapeutics Inc., which has about 66 employees.
What is the MCRB 52-week high?
The 52-week high for MCRB is $18.86 and the 52-week low is $1.20. The stock is currently 93.4% below its high.